Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05083169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: MajesTEC-3
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025 · Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 8 of 20 entries · 1 more Show 4 more changesShow less
    • Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 8 of 20 entries
    • Site details revised at 6 of 176 sites
  2. Study sites revised (176)v64 See this version in full on ClinicalTrials.gov ↗
  3. Primary completion moved earlier from Dec 8, 2028 to Sep 15, 2025 Completion moved earlier from Dec 8, 2028 to Sep 15, 2028 · Site details revised at 1 of 176 sitesv63 Show 2 more changesShow less
    • Completion moved earlier from Dec 8, 2028 to Sep 15, 2028
    • Site details revised at 1 of 176 sites
  4. Re-verified, no change to tracked fieldsv62
  5. Study sites: 174 to 176v61
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (174)v60 See this version in full on ClinicalTrials.gov ↗
  2. Re-verified, no change to tracked fieldsv59
  3. Study sites revised (174)v58 See this version in full on ClinicalTrials.gov ↗
  4. 2 versions Re-verified since Nov 6, 2025, no change to tracked fieldsv56-v57
  5. Primary completion date: Aug 1, 2025 to Dec 8, 2028 Study sites revised (174)v55 Show 1 more changeShow less
    • Study sites revised (174)

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites revised (174)v54 See this version in full on ClinicalTrials.gov ↗
  7. 2 versions Re-verified since May 22, 2025, no change to tracked fieldsv52-v53
  8. Study sites revised (174)v51 See this version in full on ClinicalTrials.gov ↗
  9. 3 versions Re-verified since Feb 27, 2025, no change to tracked fieldsv48-v50
  10. Site details revised at 1 of 174 sitesv47
  11. Study sites revised (174)v46 See this version in full on ClinicalTrials.gov ↗
  12. Re-verified, no change to tracked fieldsv45
  13. Study sites revised (174)v44 See this version in full on ClinicalTrials.gov ↗
  14. Re-verified, no change to tracked fieldsv43
  15. Study sites revised (174)v42 See this version in full on ClinicalTrials.gov ↗
  16. Study sites revised (174)v41 See this version in full on ClinicalTrials.gov ↗
  17. Study sites revised (174)v40 See this version in full on ClinicalTrials.gov ↗
  18. Study description shortened, about 145 words Site details revised at 2 of 174 sitesv39 Show 1 more changeShow less
    • Site details revised at 2 of 174 sites

    See this version in full on ClinicalTrials.gov ↗

  19. Study sites revised (174)v38 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (174)v37 See this version in full on ClinicalTrials.gov ↗
  21. Study sites revised (174)v36 See this version in full on ClinicalTrials.gov ↗
  22. Study sites revised (174)v35 See this version in full on ClinicalTrials.gov ↗
  23. Study sites revised (174)v34 See this version in full on ClinicalTrials.gov ↗
  24. Completion date: Oct 1, 2026 to Dec 8, 2028 Study sites revised (174)v33 Show 1 more changeShow less
    • Study sites revised (174)

    See this version in full on ClinicalTrials.gov ↗

  25. Study sites revised (174)v32 See this version in full on ClinicalTrials.gov ↗
  26. Study sites revised (174)v31 See this version in full on ClinicalTrials.gov ↗
  27. Re-verified, no change to tracked fieldsv30
  28. Study sites revised (174)v29 See this version in full on ClinicalTrials.gov ↗
  29. Primary completion date: Jul 7, 2024 to Aug 1, 2025 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 560 to confirmed 587 · Study sites: 176 to 174v28 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 560 to confirmed 587
    • Study sites: 176 to 174
  30. Study sites revised (176)v27 See this version in full on ClinicalTrials.gov ↗
  31. Site details revised at 5 of 176 sitesv26
  32. Site details revised at 1 of 176 sitesv25
  33. Study sites revised (176)v24 See this version in full on ClinicalTrials.gov ↗
  34. Site details revised at 3 of 176 sitesv23
  35. Study sites revised (176)v22 See this version in full on ClinicalTrials.gov ↗
  36. Enrollment target: 630 to 560 Study sites: 199 to 176v21 Show 1 more changeShow less
    • Study sites: 199 to 176
  37. Study description shortened, about 13 words Study sites revised (199) · Study arms: 3 to 2v20 Show 2 more changesShow less
    • Study sites revised (199)
    • Study arms: 3 to 2

    See this version in full on ClinicalTrials.gov ↗

  38. Re-verified, no change to tracked fieldsv19
  39. Study sites revised (199)v18 See this version in full on ClinicalTrials.gov ↗
  40. Study sites revised (199)v17 See this version in full on ClinicalTrials.gov ↗
  41. Study sites revised (199)v16 See this version in full on ClinicalTrials.gov ↗
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Trial Details
NCT Number NCT05083169
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 587 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov